Findings from Taskén group covered by NRK: Use of beta-blockers reduce prostate cancer specific mortality

Kristin Austlid Taskén ((left) and Helene Hartvedt Grytli

The group of Urological Molecular Biology at Department of Tumor Biology has recently shown that use of beta-blockers reduced prostate cancer specific mortality in prostate cancer patients on hormonal therapy. The data was obtained by combining data from the Oslo II health survey with information from the Cancer Registry of Norwegian and Statistics Norway.
These findings has been given nationwide attention through an article presented on the web page of the Norwegian Broadcasting Corporation, entitled "Blood pressure medication may help against prostate cancer".


Grytli HH, Fagerland MW, Fosså SD, Taskén KA, Håheim LL
Use of
β-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy
Prostate. 2012 (in press) [Epub ahead of print]

Article from the Norwegian Broadcasting Corporation (in Norwegian):
Blodtrykksmedisin kan hjelpe mot prostatakreft ("Blood pressure medication may help against prostate cancer")

The Group of Urological Molecular Biology, headed by Kristin Austlid Taskén

Department of Tumor Biology

Institute for Cancer Research


Page visits: 6498